secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0001171843-25-005265
Event type: leadership
Sentiment:  negative
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst's Chief R&D Officer resigns after CEO selection process; to depart Sep 1, 2025
--------------------------------------------------------------------------------

- Dr. Helen Thackray resigns as Chief R&D Officer effective Sep 1, 2025, after not being selected as next CEO.
- Separation benefits include 1 year base salary, 2025 bonus (actual and target), 12 months health coverage, outplacement, accelerated equity vesting.
- Consulting agreement for transition through Dec 31, 2025: monthly fee $12,500, continued equity vesting during period.
- No disagreement cited with Board or management regarding company operations or policies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184325005265/0001171843-25-005265-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184325005265/f8k_081125.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-005265

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer